Veritas Bio, a biotechnology holding company established by two co-founders of expressed RNAi firm Nucleonics, said this week that the US Patent and Trademark Office has issued a notice of allowance on a patent application covering a novel liver-directed RNAi delivery technology.

Poised to receive a patent on the technology, Veritas is now on the lookout for companies interested in licensing the delivery approach for use within their own RNAi research and development programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.